GSK allowed access to DiscoveRx' PathHunter ß-Arrestin parental cell lines and reagents

Download PDF Copy

Editorial Checklist

Reviewed

Oct 1 2009

NewsGuard 100/100 Score

DiscoveRx Corp. announced today the signing of a global agreement with GSK, a leading pharmaceutical company, to provide access to its PathHunter™ ß-Arrestin parental cell lines, clones and associated reagents for use in GSK’s internal GPCR Screening and Profiling efforts.

The agreement was announced soon after the announcement of a major industrial/academic collaboration that includes Medical Research Council, GSK, and DiscoveRx around GPCR orphan program. DiscoveRx further stated that this agreement is in addition to other similar agreements signed with other major drug discovery organizations which further validates PathHunter™ ß-Arrestin as a key platform to study GPCR biology.

Source:

http://www.discoverx.com

Posted in: Pharmaceutical News

Tags: B Cell, Cell, Drug Discovery, GPCR, Medical Research, Pharmaceuticals, Reagents, Research, T-Cell

Comments (0)

Download PDF Copy

Suggested Reading

SCimilarity revolutionizes single-cell data analysis with rapid cross-tissue comparisons

SCimilarity revolutionizes single-cell data analysis with rapid cross-tissue comparisons

Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

Mapping human biology: Human Cell Atlas leads a new era in precision medicine

Mapping human biology: Human Cell Atlas leads a new era in precision medicine

Study links cell death pathway to cancer resistance and growth

Study links cell death pathway to cancer resistance and growth

Study sheds light on how cells repair damaged DNA

Study sheds light on how cells repair damaged DNA

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Obe-cel demonstrates strong efficacy and safety in treating leukemia

Multiomic signatures identified for rapid detection and treatment of high-risk T-ALL

Multiomic signatures identified for rapid detection and treatment of high-risk T-ALL

Targeting intracellular checkpoints to enhance NK cell immunotherapy

Targeting intracellular checkpoints to enhance NK cell immunotherapy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

DNA-based nanorobotic hand could block viruses and enable rapid diagnostics